Viral Hepatitis Flashcards Preview

Y3M - Gastro > Viral Hepatitis > Flashcards

Flashcards in Viral Hepatitis Deck (37)
Loading flashcards...
1
Q

What type of virus is hepatitis A?

A

An RNA virus

2
Q

Explain the spread of Hep A.

A

Faecal to oral or via shellfish.

It is an endemic in Africa and South America, this means that a Travel history is important.

Most infections are in childhood

3
Q

Incubation of Hep A.

A

2-6 weeks

4
Q

Symptoms of Hep A.

A

Fever, anorexia, malaise, nausea, arthralgia

And then jaundice.

Hepatomegaly

Adenopathy

5
Q

Test findings in Hep A.

A

ASt and ALT rise 22-40d after exposure.

ALT might be as high as >1000 IU/L.

It will then return to normal over 5-20 weeks.

IGM rises from day 25 and this indicates a recent infection.

IgG is detectable for life.

6
Q

Treatment of Hep A.

A

Supportive

Avoid alcohol

Rarely interferon alfa for fulminant hepatitis.

7
Q

Explain immunisation of hep A.

A

With inactivated viral protein.

1 intramuscular dose gives immunity for 1 year and then 20 years if further booster is given at 6-12 months.

8
Q

Prognosis of hep A.

A

Usually self-limiting

Fulminant hepatitis is rare and chronicity does not occur.

9
Q

What type of virus is Hep B?

A

HBV a DNA virus

10
Q

Explain the spread of Hep B.

A

Blood products

IV drug users

Sexual contact

Direct contact.

It is an endemic in Far east, Africa and Mediterranean.

11
Q

Incubation period of hep B.

A

1-6 months

(Hep A is 2-6 weeks)

12
Q

Risk groups of hep B.

A

IV drug users and their sexual partners or carers.

Health workers

Haemophiliacs

Men who have sex with men

Haemodialysis

Sexually promiscuous

Foster carers

Close familiy members of a carrier or case

Staff or residents of institutions/prisons

Babies of HBsAg +ve mothers

Adopted child from an endemic area

13
Q

Clinical features of hep B.

A

Similar to Hep A with Fever, malaise, anorexia, nausea arthralgia then jaundice, hepatosplenomegaly and adenopathy.

However the arthralgia and also urticaria are more common in hep B.

14
Q

Test findings in hep B.

A

HBsAg surface antigen is present 1-6 months after exposure.

HBeAg e-antigen is present for 1.5 to 3 months after acute illness. E-antigen implies high infectivity.

Antibodies to HBcAg (anti-HBc) imply past infection.

Antibodies to HBsAg (anti-HBs) alone implies past vaccination

HBV PCR allows monitoring of response to therapy.

15
Q

What does HBsAg persisting for over 6 months tell you?

A

This is a defining feature of carrier status.

It occurs in 5-10% of infections.

A biopsy may be indicated unless ALT is normal and HBV DNA is <2000iu/mL

16
Q

Explain vaccination of hep B.

A

Passive immunisation may be given to non-immune contacts after high-risk exposure

17
Q

Indications of hep B vaccination.

A

In the UK only at-risk groups are targetted.

Some other countries will vaccinate their whole population, regardless of endemicity.

18
Q

Complications of hep B.

A

Fulminant hepatic failure

Cirrhosis

HCC

Cholangiocarcinoma

Cryoglobulinaemia

Membranous nephropathy

Polyarteritis nodosa

19
Q

Treatment of hep B.

A

Avoid alcohol

Immunise sexual contacts

Refer all with chronic liver inflammaiton, cirrhosis or HBV DNA > 2000IU/mL for antivirals

The ai is to clear HBsAg and prevent cirrhosis and HCC.

However there is no definitive cure for Hep B, only vaccination.

20
Q

What type of virus is Hep C?

A

RNA flavivirus

21
Q

Explain the spread of Hep C.

A

Blood - transfusion, IV drug users, sexual contact

The UK prevalence is > 200000.

22
Q

Clinical features of hep C.

A

Early infection is often mild/asymptomatic

Around 85% will develop silent chronic infection

Around 25% will get cirrhosis in 20 years

Of these around 4% will develop HCC/yr

23
Q

Risk factors of progression of hep C.

A

Male

Older

Higher viral load

Use of alcohol

HIV

HBV

24
Q

Test findings in Hep C.

A

AST:ALT ratio will be <1:1 until cirrhosis develops.

Anti-HCV antibodies confirms exposure.

HCV-PCR confirms ongoing infection/chronicity.

Liver biopsy or non-invasive elastography if HCV-PCR +ve to assess the liver damage and need for treatment.

25
Q

Treatment of Hep C.

A

Sofosbuvir alone

Or

Ledipasvir

Also quit alcohol

26
Q

What type of virus is hep D?

A

Incomplete RNA virus.

27
Q

Immunisation of hep D.

A

Hep B vaccine causes immunity to hep D as well.

28
Q

Test findings in hep D.

A

Anti-HDV antibody

29
Q

Treatment of hep D.

A

Interferon alfa has limited success, this means that liver transplantation might be needed

30
Q

Complications of hep D.

A

Can cause acute liver failure and also cirrhosis.

31
Q

Complications of hep C.

A

Glomerulonephritis

Cryoglobulinaemia

Thyroiditis

Autoimmune hepatitis

PAN

Polymyositis

Prophyria cutanea tarda

And of course liver cirrhosis

32
Q

What type of virus is Hep E?

A

RNA virus similar to Hep A

33
Q

Where is hep E common?

A

Indochina

The mortality is high in pregnancy

It is associated with pigs.

Epidemics occur in Africa e.g.

34
Q

Vaccination of Hep E.

A

Available in China but not readily used in Europe.

35
Q

Diagnosis of hep E.

A

Via serology

36
Q

Treatment of hep E.

A

There no specific treatment of hep E.

37
Q

Give other infective causes of hepatitis.

A

EBV

CMV

Leptospirosis

Malaria

Q-fever

Syphilis

Yellow fever